Yahoo · Sep 29, 2026
Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex
Check out the companies making headlines yesterday:
PA
NASDAQ · PACB
Pacific Biosciences of California, Inc.
Healthcare · Medical - Devices
$2.51
Up+$0.03 (+1.20%)
Updated Oct 2, 2026, 11:03 PM
SID Score
6.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 652.12M
- P/E ratio
- -1.29
- Dividend yield
- 0.00%
- 52-week range
- $1.07 – $2.73
- Volume
- 35.87M
- Avg. volume
- 9M
Price performance · PACB
PACB price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 1, 2026
PACB closed at $2.51 after 20 trading sessions, up 93.08% for the selected period.
- Last close
- $2.51
- Period change
- +93.08%
- Period low
- $1.27
- Period high
- $2.51
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 1, 2026 | $2.34 | $2.555 | $2.32 | $2.51 | 35.87M |
| Sep 30, 2026 | $1.84 | $2.455 | $1.84 | $2.37 | 80.39M |
| Sep 29, 2026 | $1.68 | $1.85 | $1.63 | $1.83 | 17.42M |
| Sep 28, 2026 | $1.60 | $1.80 | $1.59 | $1.71 | 21.28M |
| Sep 25, 2026 | $1.57 | $1.63 | $1.52 | $1.62 | 11.37M |
| Sep 24, 2026 | $1.40 | $1.585 | $1.38 | $1.58 | 11.1M |
| Sep 23, 2026 | $1.45 | $1.47 | $1.39 | $1.41 | 5.26M |
| Sep 22, 2026 | $1.38 | $1.48 | $1.356 | $1.47 | 7.85M |
| Sep 21, 2026 | $1.37 | $1.40 | $1.34 | $1.36 | 6.13M |
| Sep 18, 2026 | $1.38 | $1.40 | $1.34 | $1.37 | 4.96M |
| Sep 17, 2026 | $1.37 | $1.43 | $1.36 | $1.38 | 6.23M |
| Sep 16, 2026 | $1.34 | $1.40 | $1.32 | $1.34 | 5.32M |
| Sep 15, 2026 | $1.36 | $1.405 | $1.335 | $1.34 | 5.6M |
| Sep 14, 2026 | $1.28 | $1.3777 | $1.28 | $1.35 | 4.72M |
| Sep 11, 2026 | $1.29 | $1.32 | $1.28 | $1.30 | 3.73M |
| Sep 10, 2026 | $1.26 | $1.31 | $1.25 | $1.27 | 4.71M |
| Sep 9, 2026 | $1.31 | $1.34 | $1.26 | $1.29 | 4.16M |
| Sep 8, 2026 | $1.34 | $1.36 | $1.30 | $1.32 | 3.99M |
| Sep 4, 2026 | $1.295 | $1.35 | $1.288 | $1.35 | 2.76M |
| Sep 3, 2026 | $1.33 | $1.35 | $1.28 | $1.30 | 5.15M |
Latest PACB news
The latest Smart Investors Daily articles mentioning PACB.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PACB research
Overview
Company profile and research snapshot.
Company profile
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $1.60
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 11, 2026 | Barclays | Underweight | — |
| Apr 14, 2026 | Barclays | Underweight | — |
| Mar 6, 2026 | Barclays | Underweight | — |
| Dec 15, 2025 | Barclays | Equal-Weight | — |
| Nov 11, 2025 | Piper Sandler | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 29, 2026
Why PacBio (PACB) Stock Is Trading Up Today
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 5.8% in the afternoon session after genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems.
Yahoo · Sep 25, 2026
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.
Yahoo · Sep 24, 2026
1 Stock Under $10 with Exciting Potential and 2 We Avoid
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
